Arteriosclerosis and Thrombosis, Vol 13, 548-554, Copyright © 1993 by American Heart Association

ARTICLES

Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a)

JK Williams, DA Bellinger, TC Nichols, TR Griggs, TF Bumol, RL Fouts and TB Clarkson
Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine, Wake Forest University, Winston, Salem, NC 27157-1040.

Lipoprotein(a) (Lp[a]) is a newly recognized risk factor for the development of coronary heart disease and stroke in human beings; however, the mechanisms by which Lp(a) increases the risk of coronary heart disease remain unclear. The purpose of this study was to examine the effects of Lp(a) on the occurrence of occlusive arterial thrombosis. Occlusive arterial thrombus formation was examined in 18 cynomolgus monkeys with high plasma Lp(a) concentrations (> 35 mg/dL, n = 6), intermediate Lp(a) concentrations (20-25 mg/dL, n = 6), and low Lp(a) concentrations (< 12 mg/dL, n = 6). A Goldblatt clamp was positioned around the left common carotid artery to produce a stenotic segment, and the artery was pinch-injured with needle holders. A 20-MHz Doppler velocity crystal, placed distal to the stenosis/injury site, was used to detect cyclic flow reductions (indicative of transient thrombosis) or permanent cessation of flow velocity (indicative of more stable occlusive thrombosis). All monkeys with high Lp(a) concentrations developed permanent cessation of flow, whereas only one of six arteries from low-Lp(a) monkeys developed permanent cessation of flow (p < 0.05). Arteries from monkeys with intermediate Lp(a) concentrations developed pronounced cyclic reductions of flow but did not progress to permanent cessation of flow. There were no differences in plasma von Willebrand factor activity among the three groups. Immunohistochemical analysis of the damaged arterial segments indicated incorporation of Lp(a) into the adventitia, media, and intima of arteries from monkeys with low and high plasma Lp(a) concentrations, as well as the presence of an occlusive thrombus in arteries that developed permanent cessation of flow.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				L. Berglund and R. Ramakrishnan Lipoprotein(a): An Elusive Cardiovascular Risk Factor Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2219 - 2226. [Abstract] [Full Text] [PDF]

				H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]

				E. M. Tabengwa, R. L. Benza, H. E. Grenett, and F. M. Booyse Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis-Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1675 - 1681. [Abstract] [Full Text] [PDF]

				J. S. Deitch, J. K. Williams, M. R. Adams, C. A. Fly, D. M. Herrington, R. E. Jordan, M. T. Nakada, J. A. Jakubowski, and R. L. Geary Effects of ß3-Integrin Blockade (c7E3) on the Response to Angioplasty and Intra-Arterial Stenting in Atherosclerotic Nonhuman Primates Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1730 - 1737. [Abstract] [Full Text] [PDF]

				K.-I. Kawano, Y. Ikeda, K. Kondo, and K. Umemura Increased cerebral infarction by cyclic flow reductions: studies in the guinea pig MCA thrombosis model Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1998; 275(5): R1578 - R1583. [Abstract] [Full Text] [PDF]

				D. A. Bellinger, J. K. Williams, M. R. Adams, E. K. Honore, and D. E. Bender Oral Contraceptives and Hormone Replacement Therapy Do Not Increase the Incidence of Arterial Thrombosis in a Nonhuman Primate Model Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 92 - 99. [Abstract] [Full Text] [PDF]

				M. J. Ryan, L. L. Emig, G. W. Hicks, R. Ramharack, M. A. Spahr, J. S. Kreick, D. W. Brammer, A. J. Chien, and J. A. Keiser Localization of Lipoprotein(a) in a Monkey Model of Rapid Neointimal Growth Arterioscler Thromb Vasc Biol, January 1, 1997; 17(1): 181 - 187. [Abstract] [Full Text]

				R. M. Lawn, A. D. Pearle, L. L. Kunz, E. M. Rubin, J. Reckless, J. C. Metcalfe, and D. J. Grainger Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice J. Biol. Chem., December 6, 1996; 271(49): 31367 - 31371. [Abstract] [Full Text] [PDF]

				A. W. Haider, F. Andreotti, G. R. Thompson, C. Kluft, A. Maseri, and G. J. Davies Serum Lipoprotein(a) Level Is Related to Thrombin Generation and Spontaneous Intermittent Coronary Occlusion in Patients With Acute Myocardial Infarction Circulation, November 1, 1996; 94(9): 2072 - 2076. [Abstract] [Full Text]

				H.G. Kraft, A. Lingenhel, S. Kochl, F. Hoppichler, F. Kronenberg, A. Abe, V. Muhlberger, D. Schonitzer, and G. Utermann Apolipoprotein(a) Kringle IV Repeat Number Predicts Risk for Coronary Heart Disease Arterioscler Thromb Vasc Biol, June 1, 1996; 16(6): 713 - 719. [Abstract] [Full Text]

				A. Ernst, M. Helmhold, C. Brunner, A. Pethö-Schramm, V. W. Armstrong, and H.-J. Müller Identification of Two Functionally Distinct Lysine-binding Sites in Kringle 37 and in Kringles 32-36 of Human Apolipoprotein(a) J. Biol. Chem., March 17, 1995; 270(11): 6227 - 6234. [Abstract] [Full Text] [PDF]

				R. L. Desmarais, I. J. Sarembock, C. R. Ayers, S. M. Vernon, E. R. Powers, and L. W. Gimple Elevated Serum Lipoprotein(a) Is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty Circulation, March 1, 1995; 91(5): 1403 - 1409. [Abstract] [Full Text]

				M. Dammerman and J. L. Breslow Genetic Basis of Lipoprotein Disorders Circulation, January 15, 1995; 91(2): 505 - 512. [Full Text]